Segasist Awaits 510(k) Clearance For "Self-Training" Auto-Contouring Tool
This article was originally published in The Gray Sheet
Executive Summary
Segasist expects FDA to decide as early as this month on a 510(k) submission for a prostate-contouring software system designed to "learn" as it goes and become more and more accurate the more it is used.
You may also be interested in...
New Products In Brief
Sequenom’s Down syndrome test
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.